-
公开(公告)号：WO2008087186A3
公开(公告)日：2008-10-23
申请号：PCT/EP2008050512
申请日：2008-01-17
Applicant: NOVO NORDISK AS , SENSFUSS ULRICH , CONDE FRIEBOES KILIAN WALDEMAR , SPETZLER JANE
Inventor： SENSFUSS ULRICH , CONDE FRIEBOES KILIAN WALDEMAR , SPETZLER JANE
CPC classification number: C07K14/68
Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
Abstract translation: 本发明涉及有效调节一种或多种黑皮质素受体类型，化合物在治疗中的用途的新型肽化合物，包括向有需要的患者施用化合物的方法，以及使用 药物制造中的化合物。 本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面特别有意义。
-
公开(公告)号：WO2005030797A3
公开(公告)日：2005-09-09
申请号：PCT/DK2004000657
申请日：2004-09-29
Applicant: NOVO NORDISK AS , CONDE-FRIEBOES KILIAN WALDEMAR , SENSFUSS ULRICH , MADSEN KJELD , JOHANSEN NILS LANGELAND , CHRISTENSEN LEIF , HANSEN THOMAS KRUSE , WULFF BIRGITTE SCHJELLERUP
Inventor： CONDE-FRIEBOES KILIAN WALDEMAR , SENSFUSS ULRICH , MADSEN KJELD , JOHANSEN NILS LANGELAND , CHRISTENSEN LEIF , HANSEN THOMAS KRUSE , WULFF BIRGITTE SCHJELLERUP
Abstract: Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-R comprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases.
Abstract translation: 提供了包含7-12个氨基酸残基的式X1-X2-X3-X4-X5-X6-X7-R'的小环肽。 所述肽是MC4受体激动剂，因此可用于治疗肥胖症和相关疾病。
-
公开(公告)号：WO2008087189A2
公开(公告)日：2008-07-24
申请号：PCT/EP2008050515
申请日：2008-01-17
Applicant: NOVO NORDISK AS , SENSFUSS ULRICH , CONDE FRIEBOES KILIAN WALDEMAR
Inventor： SENSFUSS ULRICH , CONDE FRIEBOES KILIAN WALDEMAR
CPC classification number: C07K14/68
Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to meth- ods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the in- vention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
Abstract translation: 本发明涉及有效调节一种或多种黑皮质素受体类型的新型肽化合物，该化合物在治疗中的用途，治疗方法，包括将化合物给予需要其的患者，以及用于 的化合物在制造药物中的用途。 本发明的化合物对治疗肥胖以及与肥胖有关的各种疾病或病症特别感兴趣。
-
公开(公告)号：WO2008087186A2
公开(公告)日：2008-07-24
申请号：PCT/EP2008/050512
申请日：2008-01-17
Applicant: NOVO NORDISK A/S , SENSFUSS, Ulrich , CONDE FRIEBOES, Kilian Waldemar , SPETZLER, Jane
Inventor： SENSFUSS, Ulrich , CONDE FRIEBOES, Kilian Waldemar , SPETZLER, Jane
CPC classification number: C07K14/68
Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to meth- ods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the in- vention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
Abstract translation: 本发明涉及在治疗中有效调节一种或多种黑皮质素受体类型，化合物在治疗中的用途的新型肽化合物，包括向有需要的患者施用化合物，以及使用 的药物制造中的化合物。 本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面特别有意义。
-
5.发明申请
公开(公告)号：WO2006048449A3
公开(公告)日：2006-10-19
申请号：PCT/EP2005055758
申请日：2005-11-04
Applicant: NOVO NORDISK AS , SENSFUSS ULRICH , CONDE FRIEBOES KILIAN WALDEMAR
Inventor： SENSFUSS ULRICH , CONDE FRIEBOES KILIAN WALDEMAR
CPC classification number: C07K14/68
Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
Abstract translation: 本发明涉及有效调节一种或多种黑皮质素受体类型的新型肽化合物，治疗中化合物的用途，包括向有需要的患者施用化合物的治疗方法，以及使用 药物制造中的化合物。 本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面特别有意义。
-
Patent Agency Ranking
公开(公告)号：WO2006048450A3
公开(公告)日：2006-08-31
申请号：PCT/EP2005055760
申请日：2005-11-04
Applicant: NOVO NORDISK AS , SENSFUSS ULRICH , CHRISTENSEN LEIF , CONDE FRIEBOES KILIAN WALDEMAR , PETTERSSON INGRID
Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
Abstract translation: 本发明涉及有效调节一种或多种黑皮质素受体类型，化合物在治疗中的用途的新型肽化合物，包括向有需要的患者施用化合物的方法，以及使用 药物制造中的化合物。 本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面特别有意义。
-
公开(公告)号：WO2005030797A2
公开(公告)日：2005-04-07
申请号：PCT/DK2004/000657
申请日：2004-09-29
Applicant: NOVO NORDISK A/S , CONDE-FRIEBOES, Kilian, Waldemar , SENSFUSS, Ulrich , MADSEN, Kjeld , JOHANSEN, Nils, Langeland , CHRISTENSEN, Leif , HANSEN, Thomas, Kruse , WULFF, Birgitte Schjellerup
Inventor： CONDE-FRIEBOES, Kilian, Waldemar , SENSFUSS, Ulrich , MADSEN, Kjeld , JOHANSEN, Nils, Langeland , CHRISTENSEN, Leif , HANSEN, Thomas, Kruse , WULFF, Birgitte Schjellerup
IPC: C07K7/00
Abstract: Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-R 1 comprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases.
Abstract translation: 提供了包含7-12个氨基酸残基的式X1-X2-X3-X4-X5-X6-X7-R'的小环肽。 所述肽是MC4受体激动剂，因此可用于治疗肥胖症和相关疾病。
-
公开(公告)号：WO2012101124A1
公开(公告)日：2012-08-02
申请号：PCT/EP2012/051055
申请日：2012-01-24
Applicant: NOVO NORDISK A/S , KODRA, János, Tibor , CONDE-FRIEBOES, Kilian, Waldemar , PAULSSON, Johan, Fredrik , RAUN, Kirsten
Inventor： KODRA, János, Tibor , CONDE-FRIEBOES, Kilian, Waldemar , PAULSSON, Johan, Fredrik , RAUN, Kirsten
CPC classification number: C07K14/5759 , A61K38/22 , A61K38/2264 , A61K47/48038 , A61K47/48061 , A61K47/542 , A61K47/545
Abstract: The invention relates to Leptin derivatives, compositions and therapeutic use there-of.
Abstract translation: 本发明涉及瘦蛋白衍生物，组合物和治疗用途。
-
9.发明申请
公开(公告)号：WO2010084169A3
公开(公告)日：2011-02-17
申请号：PCT/EP2010050720
申请日：2010-01-22
Applicant: NOVO NORDISK AS , TAGMOSE TINA MOELLER , GARIBAY PATRICK WILLIAM , ANDERSEN BIRGITTE , WANG JISHU , CONDE FRIEBOES KILIAN WALDEMAR , BAK-JENSEN KRISTIAN SASS , THOEGERSEN HENNING , WOELDIKE HELLE , NIELSEN PETER KRESTEN , SLAABY RITA , ZHANG XUJIA , WIECZOREK BIRGIT
Inventor： TAGMOSE TINA MOELLER , GARIBAY PATRICK WILLIAM , ANDERSEN BIRGITTE , WANG JISHU , CONDE FRIEBOES KILIAN WALDEMAR , BAK-JENSEN KRISTIAN SASS , THOEGERSEN HENNING , WOELDIKE HELLE , NIELSEN PETER KRESTEN , SLAABY RITA , ZHANG XUJIA , WIECZOREK BIRGIT
CPC classification number: A61K47/48046 , A61K38/00 , A61K47/48215 , A61K47/48284 , A61K47/543 , A61K47/60 , A61K47/643 , C07K14/50
Abstract: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B- C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.
Abstract translation: 本发明涉及成纤维细胞生长因子21（FGF21），更具体地涉及具有共价连接的式A-B-C-D-E-的白蛋白结合物的FGF21化合物的衍生物。 本发明还涉及新型FGF21类似物，以及这些FGF21衍生物和类似物的药物用途，特别是用于治疗糖尿病，血脂异常，肥胖症，心血管疾病，代谢综合征和/或非酒精性脂肪肝病（ NAFLD）。 本发明的衍生物是延长的，例如。 能够维持较长时间的低血糖水平，能够增加FGF21的体内半衰期，和/或导致FGF21的较低清除率。 本发明的衍生物优选还具有改善的氧化稳定性。
-
公开(公告)号：WO2010060901A1
公开(公告)日：2010-06-03
申请号：PCT/EP2009/065721
申请日：2009-11-24
Applicant: NOVO NORDISK A/S , LAU, Jesper F. , SENSFUSS, Ulrich , CONDE-FRIEBOES, Kilian Waldemar , WULFF, Birgitte Schjellerup
Inventor： LAU, Jesper F. , SENSFUSS, Ulrich , CONDE-FRIEBOES, Kilian Waldemar , WULFF, Birgitte Schjellerup
CPC classification number: C07K14/685 , A61K47/542 , A61K47/545
Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
Abstract translation: 本发明涉及有效调节一种或多种黑皮质素受体类型的新型肽化合物，治疗中化合物的用途，包括向有需要的患者施用化合物的治疗方法，以及使用 药物制造中的化合物。 本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面特别有意义。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.019 seconds)
